Cidara Therapeutics to Participate in November Investor ConferencesGlobeNewswireOctober 28, 2025SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak(R) platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below November investor conferences.
Details are as follows:
Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: November 11, 2025Time: 8:00 AM ETFormat: Fireside Chat
Event: Jefferies London Healthcare Conference Date: November 17, 2025Time: 4:30 PM GMTFormat: Presentation
The live webcast for the events can be accessed in the Investors section on the Company's website at https://www.cidara.com/investors/events/. Replays of the presentations will be available for at least 30 days.
Cidara will also participate in one-on-one investor meetings during the conferences.
About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak(R) platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com
MEDIA CONTACT:Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.com
COMTEX_469859500/2010/2025-10-28T08:00:03
SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak(R) platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below November investor conferences.
Details are as follows:
Event: Guggenheim 2nd Annual Healthcare Innovation ConferenceDate: November 11, 2025Time: 8:00 AM ETFormat: Fireside Chat
Event: Jefferies London Healthcare Conference Date: November 17, 2025Time: 4:30 PM GMTFormat: Presentation
The live webcast for the events can be accessed in the Investors section on the Company's website at https://www.cidara.com/investors/events/. Replays of the presentations will be available for at least 30 days.
Cidara will also participate in one-on-one investor meetings during the conferences.
About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak(R) platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com
MEDIA CONTACT:Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.com
COMTEX_469859500/2010/2025-10-28T08:00:03
0.00% $0.00
